Pegcetacoplan SWOT of C3G/primary IC-MPGN in Taiwan

Created using ChatSlide

Pegcetacoplan is the first FDA-approved treatment for C3G, aligning seamlessly with Taiwan's nephrology practices due to its broad complement inhibition. Its strengths include effective outcomes from Phase 3 trials, reducing proteinuria, and stabilizing eGFR. However, challenges such as ultra-rare prevalence, high costs, and reimbursement barriers persist in Taiwan. Opportunities exist to revolutionize the treatment landscape, prevent dialysis, and enhance precision nephrology. Nonetheless,...